In March 2019, several generic companies notified us that they had
filed abbreviated new drug applications with the US Food and Drug
Administration (FDA) seeking approval to market generic versions of
Ibrance.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pfizer-moves-us-court-against-aurobindo-pharma-dr-reddys-on-cancer-drug/articleshow/79257595.cms
No comments:
Post a Comment